Insider Selling: Vericel (NASDAQ:VCEL) Director Sells $156,690.00 in Stock

Key Points

• Director Robert Md Zerbe sold 3,000 Vericel shares for $156,690, an 8.33% reduction in his holdings; he retained 32,995 shares after the sale.
• Vericel’s third-quarter revenue increased 26% year over year to $85.37 million, and EPS of $0.27 beat the $0.06 consensus estimate. The company raised its 2026 revenue guidance to $344–$346 million.
• Shares rose 5.5% to $54.62 in Friday trading. Analysts’ consensus rating was “Moderate Buy,” with an average price target of $60.80.

Vericel Corporation (NASDAQ:VCEL - Get Free Report) Director Robert Md Zerbe sold 3,000 shares of the stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $52.23, for a total transaction of $156,690.00. Following the transaction, the director directly owned 32,995 shares of the company's stock, valued at $1,723,328.85. This represents a 8.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Vericel Trading Up 5.5%

Shares of NASDAQ:VCEL traded up $2.84 during mid-day trading on Friday, reaching $54.62. The company had a trading volume of 1,612,332 shares, compared to its average volume of 598,922. The firm has a market cap of $2.80 billion, a price-to-earnings ratio of 116.22 and a beta of 1.08. The company's 50-day moving average price is $40.74 and its 200-day moving average price is $38.80. Vericel Corporation has a one year low of $28.95 and a one year high of $55.60.

Vericel (NASDAQ:VCEL - Get Free Report) last issued its earnings results on Thursday, November 5th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.21. Vericel had a return on equity of 6.91% and a net margin of 7.91%. The firm had revenue of $85.37 million for the quarter, compared to analyst estimates of $77.95 million. During the same period in the previous year, the company posted $0.10 earnings per share. The business's revenue was up 26.5% on a year-over-year basis. On average, research analysts anticipate that Vericel Corporation will post 0.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Vericel

Hedge funds and other institutional investors have recently modified their holdings of the stock. MCF Advisors LLC increased its stake in Vericel by 293.0% in the 2nd quarter. MCF Advisors LLC now owns 782 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 583 shares during the last quarter. Ameritas Advisory Services LLC purchased a new stake in shares of Vericel in the 2nd quarter valued at about $36,000. Allworth Financial LP bought a new stake in shares of Vericel during the 2nd quarter valued at about $60,000. Meeder Asset Management Inc. bought a new stake in shares of Vericel during the 1st quarter valued at about $61,000. Finally, Integrated Wealth Concepts LLC bought a new stake in shares of Vericel during the 2nd quarter valued at about $72,000.

Key Vericel News

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Third-quarter revenue rose 26% year over year to $85.4 million, while earnings were $0.27 per share—well above analyst estimates. Net income increased 179% to $14.2 million; the company also cited record MACI sales. Vericel Q3 2026 results and guidance
• Positive Sentiment: Vericel raised its 2026 revenue guidance to $344–$346 million, above the approximately $336 million consensus, and increased its adjusted EBITDA margin guidance to 28%. Vericel Q3 2026 results and guidance
• Positive Sentiment: HC Wainwright raised its price target from $72 to $75 and reaffirmed a Buy rating, signaling continued analyst confidence after the results. HC Wainwright raises Vericel price target
• Negative Sentiment: A separate analysis described VCEL as potentially overvalued relative to its earnings support, a risk if future growth does not justify investor expectations. Analysis of Vericel’s valuation

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Truist Financial set a $65.00 target price on shares of Vericel in a research report on Friday. Weiss Ratings reissued a "hold (c)" rating on shares of Vericel in a research report on Thursday, October 29th. Wall Street Zen upgraded shares of Vericel from a "hold" rating to a "buy" rating in a research note on Saturday, July 18th. Canaccord Genuity Group set a $60.00 price target on shares of Vericel in a research note on Thursday, July 30th. Finally, TD Cowen raised their price objective on shares of Vericel from $55.00 to $58.00 and gave the stock a "buy" rating in a report on Friday, July 31st. Four investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Vericel currently has a consensus rating of "Moderate Buy" and an average target price of $60.80.

Vericel Company Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient's own cells or biologic materials to support tissue repair and healing.

Vericel's primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.